Amphastar Pharmaceuticals (AMPH) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $1.14
- Estimate
- $0.86
- Surprise
- +32.8%
- Revenue (period 2026-09-30)
- $207.6M
- Score at report (before → after)
- 5.4 → 6.1/10
Revenue source: xbrl.
How the report landed
Amphastar Pharmaceuticals (AMPH) beat the $0.86 estimate with adjusted EPS of $1.14 — a large 32.8% upside surprise. TrendMatrix's engine moved from Hold (5.4/10) to Sell at 6.1/10 after the report.
Coverage in the report window
- Amphastar Pharmaceuticals CFO Executes Insider Stock Sale — fiscal.ai, 2026-11-07
- Wells Fargo Maintains Equal-Weight on Amphastar Pharma, Raises Price Target to $25 — benzinga, 2026-11-06
- Amphastar Pharmaceuticals' Board Authorizes A $50M Increase To The Company's Share Buyback Program — benzinga, 2026-11-05
Where TrendMatrix's rating stands now
TrendMatrix currently rates AMPH Sell at 6.1/10.
2 of the last 4 quarters beat the estimate; this quarter's +32.8% surprise compares with a +5.0% four-quarter average. Next scheduled report: 2027-02-25.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Attractive valuation
What argues against it
- Concentration risk — Supplier: third-party BAQSIMI manufacturer
- Analyst target reached - limited upside remaining
- Consecutive earnings misses (2)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $28.49
- Stop
- $26.50
The stock trades at 13.1× trailing but 9.0× forward earnings — consensus estimates already build in a substantial earnings recovery.
Risk check: trading volume is running 1.9× its average — elevated turnover around the report window.
Model outputs from TrendMatrix’s engine as of 2026-11-07 — shown for context, not personalized investment advice.
AMPH at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Drug Manufacturers - Specialty & Generic
- Market cap
- $1.21B
- P/E (fwd)
- 9.0
- P/E (ttm)
- 13.1
- 52-week range
- $16.65–$30.79
- Off 52-week high
- 7.5%
- RSI (14)
- 67
- Volume vs avg
- 1.90×
- Score today
- 6.1/10